Kakkar V V
Thrombosis Research Institute, London, UK.
Thromb Res. 1996;81(2 Suppl):S75-7. doi: 10.1016/0049-3848(95)00232-4.
Use of low molecular weight heparins (LMWHs) is now generally accepted as an ideal method of prophylaxis against postoperative venous thromboembolism. However, the long-term effects on the development of postthrombotic deep vein insufficiency are not known. Every patient developing such complications consumes a vast amount of resources, in terms of both direct and indirect costs. Our cost-effective analysis indicates that LMWH (reviparin sodium) is most cost-saving for both direct and indirect costs, particularly in high risk patients undergoing major surgery.
目前，使用低分子量肝素（LMWHs）普遍被认为是预防术后静脉血栓栓塞的理想方法。然而，其对血栓形成后深静脉功能不全发展的长期影响尚不清楚。每一位出现此类并发症的患者，无论在直接成本还是间接成本方面，都会消耗大量资源。我们的成本效益分析表明，低分子量肝素（瑞肝素钠）在直接和间接成本方面都是最节省成本的，尤其是在接受大手术的高危患者中。
